- Email: [email protected]
5168043 Blood group antigen panel
356
PATENT ABSTRACTS
5166195 ANTISENSE INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS PHOSPHOROTHIOATE OLIGONUCLEOTIDES David Ecker assigned to ISIS Pharmaceuticals Inc Methods for modulating the expression of the HIV tat gene are disclosed comprising contacting tat RNA with oligonucleotide or oligonucleotide analog which can bind with at least a portions of the RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind to portions of the tat RNA which are of significance to the expression of the gene coding for said RNA. In accordance with a preferred embodiment, methods of treatment of human immunodefieiency virus are disclosed.
51~9~ IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY David Neville, Joshua E Scharff assigned to The United States of America as represented by the Department of Health and Human Services The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias and lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.
5168043 BLOOD GROUP ANTIGEN PANEL Carlos Cordon-Cardo, Kenneth O Lloyd, Connie L Finstad, Lloyd J Old, Mryon R Melamed, Joe Sheinfeld assigned to Sloan-Kettering Institute for Cancer Research
5166318 POLYPEPTIDE HAVING THROMBIN INHIBITING ACTIVITY Yoshio Furutani, Masaru Honjo, Akira Nakayama, Koichi Kawamura, Kazunori Ando, Michiko Hori, Keiko Fukazawa, Miura, Japan assigned to Mitsui Toatsu Chemicals Incorporated Modified HVl-type hirudinin which valine at the N-terminal end of the HV I-type hirudin and aspartic acid at the 5th residue of the N-terminal end were replaced with alanine and glutamic acid, respectively. A secretion plasmid into which a DNA sequence coding for a precursor with an addition of a secretion signal of neutral protease of Bacillus amyloliquefaciens at the Nterminal end of this modified HVl-type hirudin is integrated is introduced into bacteria of the genus Bacillus and the precursor is expressed intracellularly. The modified HVl-type hirudin can be efficiently secreted extracellularly while maintaining its high thrombin inhibiting activity.
The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewisa or Lewisb antigens, the presence of the Lewisa antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewisb antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a
357
PATENT ABSTRACTS panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), $8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).
5168044 IMMUNODIAGNOSTIC ASSAYS FOR USE IN THE DETECTION AND DETERMINATION OF MASTITIS Patrick J Joyce, Catherine A O'Sullivan, Alan G Shattock, Teresa M Sloan, Blackrock, Ireland assigned to University College Dublin Immunodiagnostic assays for the detection and determination of mastitis and sub-chemical mastitis comprise capturing neutrophils or fragments or soluble products thereof in a milk sample on an insolubilized form of a corresponding antibody, optionally using conditions whereby the cells in the milk sample are lysed. Monoclonal antibodies are provided which can be used in said assays and which are specific to neutrophils.
5168048 PENICILLIN G ACYLASE, A GENE ENCODING THE SAME AND A METHOD FOR THE PRODUCTION OF THIS ENZYME Wilhelmus J Quax, Voorschoten, Netherlands assigned to Gist-brocades NV The invention provides a gene encoding penicillin G acylase, the enzyme encoded by said gene and a method for the production of said enzyme by incorporating said gene in a host and bringing the same to expression. The gene is preferably obtained from a strain of the microorganism AIcaligenes faecalis.
5168052 METHOD FOR PRODUCING 20-DEOXOTYLOSIN Karen Cox, Eugene Seno assigned to Eli Lilly and Company
The present invention, utilizing recombinant DNA technology, provides a novel method for obtaining 20-deoxotylosin from a tylosin producing microorganism. 20-deoxotylosin is useful as an antibiotic with a microbial inhibitory activity similar to tylosin.
5168053 CLEAVAGE OF TARGETED BY R N A A S E P
RNA
Sidne Altman, Anthony C Forster, Cecilia L Guerrier-Takada assigned to Yale University It has been discovered that it is possible to target any RNA molecule for cleavage by RNase P by forming a hybrid region consisting of a short sequence of base pairs followed by a terminal 3'NCCA sequence. In the preferred embodiment, the region is formed by addition of an external guide sequence consisting of a nucleotide sequence complementary to the targeted site which includes a 3'-NCCA, wherein the sequence hybridizes to the targeted RNA to form a short sequence of double-stranded RNA under conditions promoting cleavage of the substrate at the nucleotide at the 5' side of the basepaired region by the RNase P or catalytically active equivalent thereof. Specificity is determined by the complementary sequence. The sequence is preferably ten to fifteen nucleotides in length and may contain non-complementary nucleotides to the extent this does not interfere with formation of several base pairs followed by a NCCA at the 3' end. These embodiments are particularly useful in the treatment of viral diseases and disorders associated with expression of specific proteins from mRNA. 5168061 HUMAN CHORIONIC PEPTIDASE-1 Theresa Siler-Khodr assigned to Board of Regents The University of Texas System A chorionic peptidase-1 (C-use-l) which is isolated from human placenta that inactivates the immunoreactivity of GnRH, TRH and angiotension I1. Only in the presence of dithiothreitol (DDT), a sulfhydryl agent, are oxytocin and somatostatin inactivated by this peptidase. However, C-ase-l is without effect on CRF, hCS or hCG. C-ase-l also inhibits the biological activity of GnRH, i.e. its ability to stimu-
PATENT ABSTRACTS
5166195 ANTISENSE INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS PHOSPHOROTHIOATE OLIGONUCLEOTIDES David Ecker assigned to ISIS Pharmaceuticals Inc Methods for modulating the expression of the HIV tat gene are disclosed comprising contacting tat RNA with oligonucleotide or oligonucleotide analog which can bind with at least a portions of the RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind to portions of the tat RNA which are of significance to the expression of the gene coding for said RNA. In accordance with a preferred embodiment, methods of treatment of human immunodefieiency virus are disclosed.
51~9~ IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY David Neville, Joshua E Scharff assigned to The United States of America as represented by the Department of Health and Human Services The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias and lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.
5168043 BLOOD GROUP ANTIGEN PANEL Carlos Cordon-Cardo, Kenneth O Lloyd, Connie L Finstad, Lloyd J Old, Mryon R Melamed, Joe Sheinfeld assigned to Sloan-Kettering Institute for Cancer Research
5166318 POLYPEPTIDE HAVING THROMBIN INHIBITING ACTIVITY Yoshio Furutani, Masaru Honjo, Akira Nakayama, Koichi Kawamura, Kazunori Ando, Michiko Hori, Keiko Fukazawa, Miura, Japan assigned to Mitsui Toatsu Chemicals Incorporated Modified HVl-type hirudinin which valine at the N-terminal end of the HV I-type hirudin and aspartic acid at the 5th residue of the N-terminal end were replaced with alanine and glutamic acid, respectively. A secretion plasmid into which a DNA sequence coding for a precursor with an addition of a secretion signal of neutral protease of Bacillus amyloliquefaciens at the Nterminal end of this modified HVl-type hirudin is integrated is introduced into bacteria of the genus Bacillus and the precursor is expressed intracellularly. The modified HVl-type hirudin can be efficiently secreted extracellularly while maintaining its high thrombin inhibiting activity.
The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewisa or Lewisb antigens, the presence of the Lewisa antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewisb antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a
357
PATENT ABSTRACTS panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), $8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).
5168044 IMMUNODIAGNOSTIC ASSAYS FOR USE IN THE DETECTION AND DETERMINATION OF MASTITIS Patrick J Joyce, Catherine A O'Sullivan, Alan G Shattock, Teresa M Sloan, Blackrock, Ireland assigned to University College Dublin Immunodiagnostic assays for the detection and determination of mastitis and sub-chemical mastitis comprise capturing neutrophils or fragments or soluble products thereof in a milk sample on an insolubilized form of a corresponding antibody, optionally using conditions whereby the cells in the milk sample are lysed. Monoclonal antibodies are provided which can be used in said assays and which are specific to neutrophils.
5168048 PENICILLIN G ACYLASE, A GENE ENCODING THE SAME AND A METHOD FOR THE PRODUCTION OF THIS ENZYME Wilhelmus J Quax, Voorschoten, Netherlands assigned to Gist-brocades NV The invention provides a gene encoding penicillin G acylase, the enzyme encoded by said gene and a method for the production of said enzyme by incorporating said gene in a host and bringing the same to expression. The gene is preferably obtained from a strain of the microorganism AIcaligenes faecalis.
5168052 METHOD FOR PRODUCING 20-DEOXOTYLOSIN Karen Cox, Eugene Seno assigned to Eli Lilly and Company
The present invention, utilizing recombinant DNA technology, provides a novel method for obtaining 20-deoxotylosin from a tylosin producing microorganism. 20-deoxotylosin is useful as an antibiotic with a microbial inhibitory activity similar to tylosin.
5168053 CLEAVAGE OF TARGETED BY R N A A S E P
RNA
Sidne Altman, Anthony C Forster, Cecilia L Guerrier-Takada assigned to Yale University It has been discovered that it is possible to target any RNA molecule for cleavage by RNase P by forming a hybrid region consisting of a short sequence of base pairs followed by a terminal 3'NCCA sequence. In the preferred embodiment, the region is formed by addition of an external guide sequence consisting of a nucleotide sequence complementary to the targeted site which includes a 3'-NCCA, wherein the sequence hybridizes to the targeted RNA to form a short sequence of double-stranded RNA under conditions promoting cleavage of the substrate at the nucleotide at the 5' side of the basepaired region by the RNase P or catalytically active equivalent thereof. Specificity is determined by the complementary sequence. The sequence is preferably ten to fifteen nucleotides in length and may contain non-complementary nucleotides to the extent this does not interfere with formation of several base pairs followed by a NCCA at the 3' end. These embodiments are particularly useful in the treatment of viral diseases and disorders associated with expression of specific proteins from mRNA. 5168061 HUMAN CHORIONIC PEPTIDASE-1 Theresa Siler-Khodr assigned to Board of Regents The University of Texas System A chorionic peptidase-1 (C-use-l) which is isolated from human placenta that inactivates the immunoreactivity of GnRH, TRH and angiotension I1. Only in the presence of dithiothreitol (DDT), a sulfhydryl agent, are oxytocin and somatostatin inactivated by this peptidase. However, C-ase-l is without effect on CRF, hCS or hCG. C-ase-l also inhibits the biological activity of GnRH, i.e. its ability to stimu-